Introduction: Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing’s Disease (CD). In previous studies and meta-analysis, first-generation SRLs were reported to be able to induce significant tumor shrinkage only in somatotroph adenomas. This systematic review and meta-analysis aim to summarize the effect of PAS on the shrinkage of the pituitary adenomas in patients with acromegaly or CD. Materials and methods: We searched the Medline database for original studies in patients with acromegaly or CD receiving PAS as monotherapy, that assessed the proportion of significant tumor shrinkage in their series. After data extraction and analysis, a random-effec...
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for...
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for...
CONTEXT: Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly dia...
The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to...
Background: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primar...
<div><h3>Background</h3><p>The long-acting somatostatin analogue octreotide is used either as an adj...
CONTEXT: Criteria to define the response to somatostatin (SS) analogs (SSA) in acromegaly are based...
textabstractSomatostatin receptors are an important target for medical treatment of pituitary and ne...
Background: Pasireotide is a second-generation somatostatin (SRIF) receptor ligand (SRL), approved f...
Background: Pasireotide is a novel somatostatin analogue with higher affinity to 4/5 known human som...
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for...
BACKGROUND AND OBJECTIVE: The therapeutic efficacy of lanreotide SR and octreotide LAR has been stud...
BACKGROUND AND OBJECTIVE: The therapeutic efficacy of lanreotide SR and octreotide LAR has been stud...
Background: Pasireotide is a novel somatostatin analogue with higher affinity to 4/5 known human som...
CONTEXT: Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly dia...
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for...
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for...
CONTEXT: Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly dia...
The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to...
Background: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primar...
<div><h3>Background</h3><p>The long-acting somatostatin analogue octreotide is used either as an adj...
CONTEXT: Criteria to define the response to somatostatin (SS) analogs (SSA) in acromegaly are based...
textabstractSomatostatin receptors are an important target for medical treatment of pituitary and ne...
Background: Pasireotide is a second-generation somatostatin (SRIF) receptor ligand (SRL), approved f...
Background: Pasireotide is a novel somatostatin analogue with higher affinity to 4/5 known human som...
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for...
BACKGROUND AND OBJECTIVE: The therapeutic efficacy of lanreotide SR and octreotide LAR has been stud...
BACKGROUND AND OBJECTIVE: The therapeutic efficacy of lanreotide SR and octreotide LAR has been stud...
Background: Pasireotide is a novel somatostatin analogue with higher affinity to 4/5 known human som...
CONTEXT: Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly dia...
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for...
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for...
CONTEXT: Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly dia...